Incyte DGKα compound 17

Incyte DGKα compound 17: sourced facts only. name: "Systematic SAR studies led to the discovery of lead compound 17, a potent dual DGKα/ζ inhibitor with balanced in vitro ADME properties and favorable pharmacokinetic profiles." [PMID:40974316]; target: "Systematic SAR studies led to the discovery of lead compound 17, a potent dual DGKα/ζ inhibitor with balanced in vitro ADME properties and favorable pharmacokinetic profiles." [PMID:40974316]; developer: "Incyte Research Institute, Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, Delaware 19803, United States." [PMID:40974316]; stage: "The in vivo functional activity of compound 17 was demonstrated in an OT-1 pharmacodynamic murine model, showing robust and dose-dependent immune activation in the presence of antigen presentation." [PMID:40974316]